<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674412</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 15-544</org_study_id>
    <nct_id>NCT02674412</nct_id>
  </id_info>
  <brief_title>Buspirone for Functional Dysphagia</brief_title>
  <official_title>Placebo-controlled, Randomized, Double-blind, Cross-over Style Trial of Buspirone in Functional Dysphagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the utility of buspirone in patients who have a diagnosis of functional
      dysphagia. All participants will be randomized to receive either a placebo pill or buspirone.
      Subsequently, we will evaluate whether their swallowing is improved. Participants who were
      randomized to receive placebo will then receive buspirone and those who were receiving
      buspirone will receive placebo. We will again evaluate whether their swallowing improved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buspirone helps to modulate molecules which can affect the activity of the muscles in the
      esophagus. Studies in the past have shown that in healthy people, buspirone can improve the
      vigor with which the esophagus squeezes to propel food into the stomach. In patients with
      functional dysphagia, the esophagus muscles may be weak (as defined by manometry).

      Our two phase study will evaluate both symptoms of difficulty swallowing and the vigor with
      which the esophagus propels a bolus in patients after they 1) receive placebo pills and 2)
      receive buspirone pills.

      We hypothesize that the placebo pills will not affect the vigor of the muscles or the
      symptoms of difficulty swallowing, but that buspirone will improve both outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">April 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry</measure>
    <time_frame>Change in the score from Baseline to 14 days</time_frame>
    <description>DCI is a measure of the strength of muscle contractions in the esophagus while swallowing. It is measured in mm Hg, and values greater than 450mm Hg are considered Normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire Score</measure>
    <time_frame>Change in the score from Baseline to 14 days</time_frame>
    <description>A 16-question questionnaire with a score range from 0 to 80, with higher scores indicating worse outcomes (more severe symptoms of GERD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.</measure>
    <time_frame>14 days</time_frame>
    <description>A normal swallow is defined as a swallow with a Distal Contractile Index greater than 450mm Hg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Functional Dysphagia</condition>
  <condition>Ineffective Esophageal Motility</condition>
  <arm_group>
    <arm_group_label>Buspirone then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Buspirone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <arm_group_label>Buspirone then Placebo</arm_group_label>
    <arm_group_label>Placebo then Buspirone</arm_group_label>
    <other_name>Buspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic</description>
    <arm_group_label>Buspirone then Placebo</arm_group_label>
    <arm_group_label>Placebo then Buspirone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IEM per Chicago Classification, v3.0 criteria - as noted above

          -  Esophagogastroduodenoscopy (EGD) negative for mechanical obstruction

          -  Esophageal biopsies negative for eosinophilic esophagitis

        Exclusion Criteria:

          -  Pregnant women

          -  Prisoners

          -  Currently on other serotonin modulating medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <results_first_submitted>June 14, 2018</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2018</results_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Scott Gabbard, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02674412/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buspirone Then Placebo</title>
          <description>Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Buspirone</title>
          <description>Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed for each subject during two separate periods--once while on Buspirone and once while on Placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants who enrolled in and completed the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry</title>
        <description>DCI is a measure of the strength of muscle contractions in the esophagus while swallowing. It is measured in mm Hg, and values greater than 450mm Hg are considered Normal.</description>
        <time_frame>Change in the score from Baseline to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>All participants in the study, while taking Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants on the study, while taking placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry</title>
          <description>DCI is a measure of the strength of muscle contractions in the esophagus while swallowing. It is measured in mm Hg, and values greater than 450mm Hg are considered Normal.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.9" spread="771.7"/>
                    <measurement group_id="O2" value="340.4" spread="761.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire Score</title>
        <description>A 16-question questionnaire with a score range from 0 to 80, with higher scores indicating worse outcomes (more severe symptoms of GERD).</description>
        <time_frame>Change in the score from Baseline to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>All participants in the study, while taking Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants in the study, while taking placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire Score</title>
          <description>A 16-question questionnaire with a score range from 0 to 80, with higher scores indicating worse outcomes (more severe symptoms of GERD).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="22.2"/>
                    <measurement group_id="O2" value="-10.2" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.</title>
        <description>A normal swallow is defined as a swallow with a Distal Contractile Index greater than 450mm Hg</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>All participants in the study, while taking Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants in the study, while taking placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.</title>
          <description>A normal swallow is defined as a swallow with a Distal Contractile Index greater than 450mm Hg</description>
          <units>percentage of swallows</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="37"/>
                    <measurement group_id="O2" value="20" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buspirone</title>
          <description>Buspirone 10 mg PO TID
Buspirone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Tablet TID
Placebo: Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Gabbard, MD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216 444-6523</phone>
      <email>gabbars@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

